Commentary on variability in vitamin K antagonist metabolism

By Smith Dennis A  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 2, Iss. 1, 2006-02 ,pp. : 1-2

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

Warfarin overdose: Diminished vitamin K response in an elderly patient with a CYP2C9*3*3 genotype: case report

By  

Reactions Weekly, Vol. 1, Iss. 1279, 2009-01 ,pp. : 34-35

Adis International

Access to resources Recommend Favorite

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians

By Borgiani Paola   Ciccacci Cinzia   Forte Vittorio   Romano Silvia   Federici Giorgio   Novelli Giuseppe  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1545-1550

Future Medicine

Access to resources Recommend Favorite